Osteoporosis can strike people of any age and ethnicity and is a
major public health threat for an estimated 44 million Americans,
68 percent of them women. In the U.S. today, 10 million individuals
are estimated to already have the disease and almost 34 million
more are thought to have low bone mass, placing them at increased
risk for this disease. Fast, convenient and simple to perform, our
Osteomark NTx ELISAs provide an accurate
measurement of bone resorption aiding in the diagnosis and
monitoring of osteoporosis patients and in predicting accelerated
decrease in bone mass in postmenopausal women. When used in
conjunction with bone mineral density (BMD), Osteomark NTx gives a
more complete picture of bone status than either technology alone.
Both urine and serum test kits are available.